The combination of two specific drugs has given the best results and is easier for patients than traditional treatment.
In the UK, a large -scale study is conducted, which can radically change the approach to the treatment of chronic lymphocytic leukemia -the most common form of leukemia in adults, reports The Guardian.
The results of the Flair test, conducted at 96 oncoccent nationwide, have shown that a new approach without chemotherapy is more effective and better tolerated by patients.
The study was attended by 786 patients who had not been treated. They are randomly divided into three groups: one receives common chemotherapy, the second – only the drug to be used, and the third – the combination of Ibrutinib and Venotoklax. Treatment is selected uniquely based on blood tests.
Five years after the start of the study, 94% of patients who received a combination of drugs were left without the development of the disease. For comparison, in patients who take only the Ibrutinib, this indicator is 79%, and among those undergoing chemotherapy – 58%.
In addition, in 66% of patients undergoing combined treatment, two years later, bone cancer cells have not been detected. It is impossible to record any patient who received only the Ibrutinib, and only 48% of those who undergo chemotherapy.
Ibrutinib prevents signals that use cancer cells for growth, and Venotoklax blocks a protein that supports the safety of lymphocytic leukemia cells.
According to leading researchers, hematologist Talhi Munir from Lida University Hospital, the Flair Test is a point proving the effectiveness of a personalized, less toxic approach to therapy.
Research financing was provided by Cancer Research UK, as well as Abbvie and Johnson & Johnson Pharmaceutical Company.
We remind you, earlier it was reported that in the United States approved a blood test for Alzheimer’s disease.
A new broad version of Covid-19 quickly spreads the world
News from CORRESPONDENT.NET On the telegram and whatsapp. Subscribe to our channels https://t.me/KorresPondentNet and WhatsApp
Source: korrespondent
I am Ben Stock, a passionate and experienced digital journalist working in the news industry. At the Buna Times, I write articles covering technology developments and related topics. I strive to provide reliable information that my readers can trust. My research skills are top-notch, as well as my ability to craft engaging stories on timely topics with clarity and accuracy.